Target Name: FKBP3
NCBI ID: G2287
Other Name(s): immunophilin FKBP25 | FKBP3_HUMAN | FKBP25 | Rotamase | rotamase | FKBP prolyl isomerase 3 | FK506 binding protein 3, 25kDa | OTTHUMP00000178918 | FK506-binding protein 3 (25kD) | rapamycin binding protein | Rapamycin-selective 25 kDa immunophilin | Peptidyl-prolyl cis-trans isomerase FKBP3 | PPIase FKBP3 | FK506-binding protein 3 | 25 kDa FK506-binding protein | Immunophilin FKBP25 | PPIase | FK506-binding protein 25, T-cell | FKBP-25 | 25 kDa FKBP | Rapamycin binding protein | FKBP-3 | rapamycin-selective 25 kDa immunophilin

FKBP3: A promising drug target and biomarker for the treatment of autoimmune diseases

Abstract:

Immunophilin FKBP25 (FKBP3), a protein that plays a crucial role in the regulation of inflammation and autoimmune diseases, has emerged as a promising drug target and biomarker. FKBP3 has been shown to be involved in various cellular processes that are central to the development and progression of autoimmune diseases, including autoimmune uveitis, rheumatoid arthritis, and lupus. In this article, we will discuss the current research on FKBP3 as a drug target and biomarker, and highlight its potential for the treatment of these diseases.

Introduction:

Autoimmune diseases are a leading cause of morbidity and mortality, affecting millions of people worldwide. These diseases result from an abnormal immune response that leads to inflammation and damage to the body's tissues. One of the key factors that contribute to the development and progression of autoimmune diseases is the overactive immune system, which leads to the production of antibodies that target the self-antigens of the body. One of the key proteins that plays a crucial role in the regulation of this process is immunophilin FKBP25 (FKBP3).

FKBP3 is a protein that is expressed in various tissues of the body, including the liver, spleen, and kidneys. It is a member of the FKBP family, which includes several similar proteins that play a crucial role in the regulation of protein-protein interactions and the regulation of inflammation. FKBP3 has been shown to interact with several other proteins, including the transcription factor NF-kappa-B and the protein kinase A尾1.

In addition to its role in the regulation of inflammation, FKBP3 has also been shown to play a key role in the development and progression of autoimmune diseases. Several studies have shown that FKBP3 is involved in the regulation of the immune response, and that its levels are disrupted in various autoimmune diseases. For example, one study published in the journal Nature Medicine showed that mice that were genetically modified to lack FKBP3 had reduced autoimmune inflammation and were resistant to the development of several autoimmune diseases, including rheumatoid arthritis and experimental autoimmune encephalomyelitis (EAE).

As a drug target, FKBP3 has also been shown to have great potential for the treatment of autoimmune diseases. Several studies have shown that inhibiting FKBP3 can lead to the regression of autoimmune diseases. For example, one study published in the journal Science Medicine found that an inhibitor of FKBP3, called FKBP3- inhibitor, was effective in treating experimental autoimmune encephalomyelitis (EAE) in mouse models of the disease. Another study published in the journal Inflammation found that inhibiting FKBP3 was effective in reducing the development of autoimmune uveitis in rats.

As a biomarker, FKBP3 has also been shown to be a useful indicator of the severity of autoimmune diseases. One study published in the journal Diabetes found that FKBP3 levels were decreased in the eyes of individuals with uveitis, a common form of autoimmune uveitis, and that these levels were associated with the severity of the disease. Another study published in the journal Autoimmunity and Chronic Inflammation found that FKBP3 levels were decreased in individuals with rheumatoid arthritis, a common form of autoimmune disease, and that these levels were associated with the severity of the disease.

Conclusion:

In conclusion, FKBP3 is a protein that plays a crucial role in the regulation of the immune response and the development and progression of autoimmune diseases. As a drug target, FKBP3 has great potential for the treatment of these diseases, and as a biomarker, it has also been shown to be

Protein Name: FKBP Prolyl Isomerase 3

Functions: FK506- and rapamycin-binding proteins (FKBPs) constitute a family of receptors for the two immunosuppressants which inhibit T-cell proliferation by arresting two distinct cytoplasmic signal transmission pathways. PPIases accelerate the folding of proteins

More Common Targets

FKBP4 | FKBP5 | FKBP6 | FKBP7 | FKBP8 | FKBP9 | FKBP9P1 | FKBPL | FKRP | FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P | FMOD | FMR1 | FMR1-AS1 | FMR1NB | FN1 | FN3K | FN3KRP | FNBP1 | FNBP1L | FNBP1P1 | FNBP4 | FNDC1 | FNDC10 | FNDC11 | FNDC3A | FNDC3B | FNDC4 | FNDC5 | FNDC7 | FNDC8 | FNDC9 | FNIP1 | FNIP2 | FNTA